Oncothyreon (ONTY) Announces Proposed Stock Offering
Tweet
Share
E-mailGet Alerts ONTY Hot Sheet
Join SI Premium – FREE
Oncothyreon Inc. (NASDAQ: ONTY) announced its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. Oncothyreon also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any.
The proceeds of the offering will primarily be used to fund the development of PX-866, Oncothyreon's PI-3 Pan-isoform irreversible Kinase inhibitor, and ONT-10, Oncothyreon's proprietary follow-on vaccine to Stimuvax
The proceeds of the offering will primarily be used to fund the development of PX-866, Oncothyreon's PI-3 Pan-isoform irreversible Kinase inhibitor, and ONT-10, Oncothyreon's proprietary follow-on vaccine to Stimuvax
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
- Enliven Therapeutics, Inc (ELVN) Files for 6.43M Share Offering by Selling Stockholders
- Bio-Path Holdings (BPTH) Announces 375K Share Offering at $3.225/sh
Create E-mail Alert Related Categories
Equity OfferingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
